Aquestive Therapeutics, Inc. entered into an underwriting agreement on August 14, 2025, to offer 21,250,000 shares of common stock at $4.00 per share, expected to gross $85 million for advancing its products and general corporate needs. The offering's closing is anticipated on August 15, 2025.